https://scholars.lib.ntu.edu.tw/handle/123456789/496070
標題: | Metformin use and cervical cancer risk in female patients with type 2 diabetes | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Cervical cancer; Diabetes mellitus; Metformin; Taiwan | 公開日期: | 2016 | 出版社: | Impact Journals LLC | 卷: | 7 | 期: | 37 | 起(迄)頁: | 59548-59555 | 來源出版物: | Oncotarget | 摘要: | This study evaluated whether metformin may affect the risk of cervical cancer. The reimbursement databases of the Taiwan's National Health Insurance were used. Female patients with type 2 diabetes at an onset age of 25-74 years during 1999- 2005 and newly treated with metformin (n=132971, "ever users of metformin") or other antidiabetic drugs (n=6940, "never users of metformin") were followed for at least 6 months until December 31, 2011. The treatment effect of metformin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Analyses were also conducted in a 1:1 matched pair cohort based on 8 digits of propensity score. Results showed that the respective numbers of incident cervical cancer in ever users and never users were 438 (0.33%) and 38 (0.55%), with respective incidences of 68.29 and 121.38 per 100,000 person-years. The overall hazard ratio suggested a significantly lower risk in metformin users (0.558, 95% confidence intervals: 0.401-0.778). In tertile analyses, the hazard ratios (95% confidence intervals) for the first (<23.0 months), second (23.0-47.9 months) and third (>47.9 months) tertile of cumulative duration were 1.272 (0.904-1.790), 0.523 (0.366-0.747) and 0.109 (0.070-0.172), respectively. Findings were supported by the analyses in the matched cohort. In conclusion, metformin may significantly reduce the risk of cervical cancer, especially when the cumulative duration is more than 2 years. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991358660&doi=10.18632%2foncotarget.10934&partnerID=40&md5=7252c39ac9fb479dfffc5d07500fda7e https://scholars.lib.ntu.edu.tw/handle/123456789/496070 |
ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.10934 | SDG/關鍵字: | insulin; metformin; pioglitazone; rosiglitazone; sulfonylurea; antidiabetic agent; metformin; adult; aged; Article; cancer incidence; cancer risk; cohort analysis; controlled study; female; human; major clinical study; national health insurance; non insulin dependent diabetes mellitus; probability; propensity score; proportional hazards model; risk reduction; Taiwan; uterine cervix cancer; chemically induced; incidence; middle aged; non insulin dependent diabetes mellitus; outcome assessment; procedures; statistics and numerical data; uterine cervix tumor; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Metformin; Middle Aged; Outcome Assessment (Health Care); Propensity Score; Proportional Hazards Models; Taiwan; Uterine Cervical Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。